PEG & ADCs
- FDA Approved Antibody-Drug Conjugates (ADCs) By 2026
- 21 Antibody-drug Conjugates (ADCs) Approved by FDA/EMA/NMPA/PMDA
- What Are ADC Linkers: Cleavable vs. Non-Cleavable Linkers
- Antibody–Drug Conjugate Payloads: MMAE & MMAF
- Nectin-4: New Antibody-Drug Conjugate (ADC) Target
- Summary of Approved HER2 ADCs on The Market & in Clinical Trials
- Beyond HER3-DXd: New Frontiers in HER3-Targeted Therapies for Lung Cancer
- Dual-Payload ADCs: A Revolutionary Leap in Targeted Cancer Therapy
- Trodelvy: Breast Cancer Breakthrough & Beyond (Trop-2 ADC)
- Three ADCs Expected To Be Approved In 2024-2025